Skip to main content
SpringerLink
Log in

Sequence-dependent growth-inhibitory effects of the in vitro combination of fluorouracil, cisplatin, and dipyridamole

  • Original Articles
  • Fluorouracil, Cisplatin, Dipyridamole, Cytotoxicity
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

The present study was designed to analyze the growth-inhibitory effects of the combination of fluorouracil (FUra), cisplatin (CDDP), and dipyridamole (DP). These toxic effects were assessed on the human breast-carcinoma cell line MCF-7 using the MTT (tetrazolium bromide) assay in 96-well culture dishes. Data were analyzed using the median-effect principle. The drug combinations tested included FUra concentrations ranging from 0.8 to 800 nmol/l, CDDP concentrations of 0.3–30 μmol/l, and DP concentrations of 2–200 μmol/l. A total of 189 different experimental conditions were tested, including different sequences of administration, with being DP applied before, simultaneously with, or after the two antitumor drugs. Synergistic cytotoxic interactions were found between FUra and CDDP, FUra and DP, and CDDP and DP as well as when the three drugs were combined. The sequence of exposure did not influence the growth-inhibitory activity of the combination FUra-CDDP but altered the effect of combinations of either FUra or CDDP with DP, since at lower concentrations the effect shifted from synergism to antagonism when DP was added simultaneously with CDDP and after the two antitumor drugs. However, the interaction was shown to be truly synergistic by median-effect analysis when the two antitumor drugs were simultaneously associated, with no change in the synergistic effect being observed for the three DP administration sequences.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

FUra:

fluorouracil

CDDP:

cisplatin,cis-diamminedichloroplatinum(II)

MTT:

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (azolyl blue); IC50, concentration inducing 50% inhibition of cell growth; fa, fraction affected; fu, fraction unaffected

Cl:

combination index

References

  1. Barberi M, Merlin JL, Weber B (1991) Sensitive determination of free and plasma protein-bound dipyridamole by high-performance liquid chromatography. J Chromatogr Biomed Appl 565: 511–515

    Google Scholar 

  2. Barberi-Heyob M, Merlin JL, Weber B (1992) Intraperitoneal injection of dipyridamole increases the life span of tumor bearing mice treated with fluorouracil. In Vivo 6: 535–540

    Google Scholar 

  3. Barberi M, Merlin JL, Weber B (1990) Preclinical studies of fluorouracil-dipyridamole association in human cell lines and in mice. J Cancer Res Clin Oncol 116 [Suppl 1]: S620

    Google Scholar 

  4. Chan TCK, Gordon LC, Solomon Z, Stephen C, Stephen BH (1988) Pharmacokinetics of intraperitoneally asministered dipyridamole in cancer patients. Cancer Res 48: 215–218

    Google Scholar 

  5. Chou TC, Talalay P (1984) Quantitative analysis of dose effect relationship: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27

    Google Scholar 

  6. Chou TC, Talalay P (1987) Application of the median-effect principle for the assessment of low dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents. In: Harrap KR, Connors TA (eds) New avenues in developmental cancer chemotherapy. Academic Press, New York, p 37

    Google Scholar 

  7. Desai PB, Sridhar R (1989) Effect of chemical modifiers on the toxicity of mitoxantrone towards CHO-K-a cells in vitro. Proc Am Assoc Cancer Res 30: 559

    Google Scholar 

  8. Galabov AS, Mastikova M (1991) Dipyridamole is an interferon inducer. Acta Virol 26: 137–147

    Google Scholar 

  9. Grem JL, Fischer PH (1986) Alteration of fluorouracil metabolism in human colon cancer cells by dipyridamole with a selective increase in fluorodeoxyuridine monophosphate levels. Cancer Res 46: 6192–6199

    Google Scholar 

  10. Howell SB, Hom DK, Sanga R, Vick JS, Chan TCK (1989) Dipyridamole enhancement of etoposide sensitivity. Cancer Res 49: 4147–4153

    Google Scholar 

  11. Howell SB, Hom DK, Sanga R, Vick JS, Abramson JS (1989) Comparison of the synergistic potentiation of etoposide, doxorubicin, and vinblastine cytotoxicity by dipyridamole. Cancer Res 49: 3178–3183

    Google Scholar 

  12. Howell SB, Isonishi S, Christen RC, Andrews PA, Mann SC (1991) Cellular pharmacology strategies for overcoming drug resistance: potential applications to regional therapy. Eur J Surg [Suppl] 561: 45–48

    Google Scholar 

  13. Jekumen A, Vick J, Sanga R, Chan TCK, Howell SB (1992) Synergism between dipyridamole and cisplatin in human carcinoma cells in vitro. Cancer Res 52: 3566–3571

    Google Scholar 

  14. Keane TE, Rosner GL, Gingrich JR, Poulton SHM, Walther PJ (1991) The therapeutic impact of dipyridamole chemopotentiation of the cytotoxic combination 5-fluorouracil/cisplatin in an animal model of human bladder cancer. J Urol 146: 1418–1424

    Google Scholar 

  15. King ME, Narporn A, Young B, Howell SB (1984) Modulation of cytarabine uptake and toxicity by dipyridamole. Cancer Treat Rep 68: 361–366

    Google Scholar 

  16. Kong XB, Chou JH, Kim H, Chou TC (1992) Computerized quantitation of synergism and antagonism in three drug combinations. Proc Am Assoc Cancer Res 33: 442

    Google Scholar 

  17. Konits PH, Aisner J, Van Echo DA (1981) Mitomycin C and vinblastine chemotherapy for advanced breast cancer. Cancer 48: 1295–1298

    Google Scholar 

  18. Mahony C, Wolfram KM, Bjornsson TD (1982) Dipyridamole kinetics. Clin Pharmacol Ther 31:330–338

    Google Scholar 

  19. Miller EM, Willson JK, Fisher PH (1987) Folinic acid alters the mechanism by which dipyridamole increases the toxicity of fluorouracil in human colon cancer cells. Proc Am Assoc Cancer Res 28: 326

    Google Scholar 

  20. Perloff M, Hart RD, Holland JF (1978) Vinblastine, Adriamycin, thiotepa and halostesin (VATH): therapy for advanced breast cancer refractory to prior chemotherapy. Cancer 42: 2534–2537

    Google Scholar 

  21. Piper AA, Nott SE, Mackinnon WB, Tattersall MH (1983) Critical modulation by thymidine and hypoxanthire of sequential methotrexate-5-fluorouracil synergism in murine L1210 cells. Cancer Res 43: 5701–5706

    Google Scholar 

  22. Rosenberg B (1985) Fundamental studies with cisplatin. Cancer 55: 2302–2307

    Google Scholar 

  23. Shionoya S, Lu Y, Scanlon KJ (1986) Properties of amino acid transport systems in K562 cells sensitive and resistant tocis-diamminedichloroplatinum(II). Cancer Res 4: 3445–3448

    Google Scholar 

  24. Tada H, Shito O, Kuroshima K, Tsukamoto K (1986) An improved colorimetric assay for interleukin 2. J Immunol Methods 93: 157–165

    Google Scholar 

  25. Wilson AP, Ford CH, Newman CE, Howell A (1987)cis-Platinum and ovarian carcinoma. In vitro chemosensitivity of cultured tumor cells from patients receiving high dosecis-platinum as first line treatment. Br J Cancer 56: 763–773

    Google Scholar 

  26. Zhen Y, Lui MS, Weber G (1983) Effects of acivicin and dipyridamole on hepatoma 3924 A cells. Cancer Res 43: 1616–1619

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre Alexis Vautrin, Avenue de Bourgogne, F-54511, Vandœuvre-Les-Nancy Cedex, France

    M. Barberi-Heyob, G. Griffon, J. L. Merlin & B. Weber

Authors
  1. M. Barberi-Heyob
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Griffon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. L. Merlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barberi-Heyob, M., Griffon, G., Merlin, J.L. et al. Sequence-dependent growth-inhibitory effects of the in vitro combination of fluorouracil, cisplatin, and dipyridamole. Cancer Chemother. Pharmacol. 33, 163–170 (1993). https://doi.org/10.1007/BF00685336

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00685336

Keywords

Search

Navigation